ASCO Preview: Are Combo Treatments With Cancer-Killing Viruses Worth The Cost?

When Amgen’s Imlygic became the first FDA-approved cancer-killing virus on the market in 2015, oncologists and Wall Street analysts alike predicted the product would ultimately work better in combination treatments than it does on its own. At closely watched annual conference of the American Society of Clinical Oncology (ASCO) in Chicago, starting today, scientists will present data from several combo trials involving the drug, which is an engineered form of the herpes virus.